Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET

Company Participants

Jonathan Kirshenbaum - Investor Relations
Sanj Patel - Chairman and Chief Executive Officer
Ross Moat - Chief Commercial Officer
Mark Ragosa - Chief Financial Officer
John Paolini - Chief Medical Officer

Conference Call Participants

Roger Song - Jefferies
Liisa Bayko - Evercore ISI
Paul Choi - Goldman Sachs
Eva Fortea-Verdejo - Wells Fargo
David Nierengarten - Wedbush Securities
Anupam Rama - JPMorgan

Operator

Good day and thank you for standing by. Welcome to Kiniksa Pharmaceuticals Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. Please be advised that today's conference is being recorded. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]

I would now like to hand the conference over to your speaker today, Jonathan Kirshenbaum, Investor Relations.

Jonathan Kirshenbaum

Thank you, operator. Good morning, everyone and thank you for joining Kiniksa call to discuss our third quarter 2024 financial results and recent portfolio execution. A press release highlighting these results can be found on our website under the Investors section.

As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. Ross Moat, our Chief Commercial Officer, will provide an update on the ARCALYST commercial execution. Then, Mark Ragosa, our Chief Financial Officer, will review our third quarter 2024 financial results. And finally, Sanj will return for closing remarks and to kick off the Q&A session, for which John Paolini, our Chief Medical Officer; and Eben Tessari, our Chief Operating Officer, will also be on the line.

Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption Risk Factors contained in our SEC filings. These statements speak only as of the date of this presentation and we undertake no obligation to update such statements, except as required by law.

With that, I will turn it over to Sanj.

Sanj Patel

Thanks, Jonathan, and good morning, everyone.

Kiniksa is a well-capitalized, growth orientated company that's well-positioned for near and long-term success. In the third quarter, we continue to drive strong commercial performance with ARCALYST including increased prescriber adoption and repeat prescriber growth. Patients and physicians continue to report high levels of satisfaction with ARCALYST and our market building activities are positioning us to provide that positive experience to more patients in need.